9 results about "Cystein protease" patented technology

The invention relates to a method or regimen comprising the administration of IgG cysteine protease to a subject in order to improve the benefit of a subsequent vector-based therapy, where the vector-based therapy treats a disease or condition in said subject. Accordingly, the invention also relates to the treatment of diseases or conditions with a vector-based therapy. The method comprises administering to the subject at least two doses of an IgG cysteine protease; and subsequently administering said vector-based therapy. Methods of the invention are particularly useful for subjects who have pre-existing immunity or pre-existing neutralizing antibodies against the vector-based therapy.

The application relates to the field of biological medicine, and particularly discloses application of a sophora japonica extract in preparation of a product for improving the reproductive performance of ewes. The sophora japonica extract can effectively inhibit pyroptosis of ovarian granulosa cells by down-regulating expression of cysteine protease B, further reverses follicle atresia and ovulation disorders caused by pyroptosis, and improves the reproductive performance; animal experiments show that the sophora japonica extract can optimize the follicle development structure of ewes, inhibit overdevelopment of large follicles, and significantly improve the ovulation efficiency, thereby providing a new scheme for inhibiting pyroptosis of ovarian granulosa cells and improving the reproductive performance of livestock.

The invention provides siRNA, a kit and a method for reducing invasion ability of ichthyophthirius multifiliis and application of the siRNA, and belongs to the technical field of molecular biology. The positive-sense strand of the siRNA disclosed by the invention is as shown in SEQ ID NO.5, and the antisense strand of the siRNA is as shown in SEQ ID NO.6. The siRNA can silence expression of cysteine protease genes of the ichthyophthirius multifiliis, and the invasion ability of the ichthyophthirius multifiliis to a host can be remarkably reduced by soaking and transfecting ichthyophthirius multifiliis bodies for 12 hours through the siRNA with the concentration of 30-100 nM; experiments prove that ichthyophthirius multifiliis infected by goldfish body surface tissues transfected with the siRNA is obviously lower than that of a control group. The invention further provides a kit containing the siRNA and a method for applying the siRNA, the siRNA can be used for reducing the invasion ability of ichthyophthirius multifiliis and protecting ichthyophthirius multifiliis hosts, an efficient and reliable molecular tool is provided for ichthyophthirius multifiliis infection prevention and control, and the application prospect is wide.

The application belongs to the technical field of molecular marker assisted breeding, and particularly relates to a corn chromosome 4 white spot disease resistance related molecular marker and application, specifically, the application provides a corn white spot disease resistance related molecular marker, the molecular marker gene is a Zm00001eb168510 gene and / or a sequence as shown in SEQ ID NO:1, a CDs sequence of the Zm00001eb168510 gene is as shown in SEQ ID NO:2, through years of experiments in multiple points, the application is co-located to a white spot disease resistance QTL qMWS4-4 interval and a resistance SNP:4-14146725 and an associated gene Zm00001eb168510 on a corn chromosome 4, the SNP site can be located in different environments through QTL linkage analysis and GWAS correlation analysis, and can explain 15.14% of the phenotype variation; the associated candidate functional gene mainly encodes a cysteine protease superfamily protein, the cysteine protease superfamily contains a deubiquitinating enzyme, and plays an important role in plant development and adversity response.

The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab′)2 fragments.

The invention provides application of MSC1094308 in preparation of a medicine for preventing and / or treating inflammasome-related diseases, and belongs to the technical field of biological medicine preparation. The Vps4B ATPase inhibitor MSC1094308 can be used for remarkably reducing the activation of cysteine proteinase-1 (Caspase-1) and the interaction between ASC protein and Caspase-1 protein in a mouse bone marrow-derived macrophage (BMDM). Therefore, the invention proves that the MSC1094308 can effectively inhibit the activation of the inflammasome, thereby providing a new means for developing medicines for treating inflammasome-related diseases.

A method for detecting a target nucleic acid in a sample, the method comprising the following steps: (a) coupling of an amplification product of the target nucleic acid, wherein said amplification product is generated if said target nucleic acid is in the sample, comprising modified nucleotides having a first reactive moiety to a second reactive moiety that is linked to a cysteine protease activator molecule to produce amplification products of the target nucleic acid labelled with a cysteine protease activator molecule; (b) optionally immobilizing the labelled amplification products on a surface; (c) contacting the optionally immobilized, labelled amplification products with a reversibly inactivated cysteine protease, wherein the catalytic cysteine residue of the reversibly inactivated cysteine protease is blocked by a disulfide bond or a selenylsulfide bond, and reactivating the proteolytic activity of said cysteine protease by said cysteine protease activator molecule by disulfide bond or selenylsulfide bond reduction; (d) contacting the reactivated cysteine protease with a cysteine protease substrate, wherein said substrate provides a detectable signal when hydrolysed by said reactivated cysteine protease; and (e) monitoring said detectable signal, wherein the presence of the detectable signal is indicative of the presence of said target nucleotide sequence in said sample.

Provided is an IdeS protein variant having IgG-cleaving cysteine protease activity and having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to SEQ ID No. 2, and (a) having a glutamic acid (E) at a position corresponding to position 226 of SEQ ID No. 1, or (b) having an arginine (R) at a position corresponding to position 167 of SEQ ID No. 1 and a glutamic acid (E) at a position corresponding to position 226 of SEQ ID No. 1. Also provided are a nucleic acid encoding the IdeS protein variant, a vector comprising the nucleic acid, and use of the IdeS protein variant for treating or preventing IgG-related diseases or disorders, or use thereof as a tool enzyme of biotechnology in vitro.

Provided are improved cysteine proteases for specifically cleaving and inactivating immunoglobulin G. The improved cysteine pro-teases are useful in methods of treating diseases, disorders or conditions characterized by excessive levels of IgG antibodies, including autoimmune disorders and candidates for organ transplantation sensitized with anti-HLA antibodies, as well as for treating candidates for gene therapy with pre-existing neutralizing antibodies against recombinant vectors and re-dosing of subjects previously treated with a gene therapy vector.